Werewolf Therapeutics Stock Today
| HOWL Stock | USD 1.09 0.04 3.54% |
PerformanceVery Weak
| Odds Of DistressVery High
|
Werewolf Therapeutics is selling for 1.09 as of the 21st of March 2025. This is a 3.54 percent decrease since the beginning of the trading day. The stock's lowest day price was 1.07. Werewolf Therapeutics has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 21st of December 2024 and ending today, the 21st of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 30th of April 2021 | Category Healthcare | Classification Health Care |
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the bodys immune system for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Cambridge, Massachusetts. The company has 44.83 M outstanding shares of which 1.87 M shares are currently shorted by private and institutional investors with about 7.11 trading days to cover. More on Werewolf Therapeutics
Moving together with Werewolf Stock
Moving against Werewolf Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
Werewolf Stock Highlights
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsWerewolf Therapeutics can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Werewolf Therapeutics' financial leverage. It provides some insight into what part of Werewolf Therapeutics' total assets is financed by creditors.
| |||||
Werewolf Therapeutics (HOWL) is traded on NASDAQ Exchange in USA. It is located in 200 Talcott Ave, Watertown, MA, United States, 02472 and employs 46 people. Werewolf Therapeutics is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 48.86 M. Werewolf Therapeutics conducts business under Biotechnology sector and is part of Health Care industry. The entity has 44.83 M outstanding shares of which 1.87 M shares are currently shorted by private and institutional investors with about 7.11 trading days to cover.
Werewolf Therapeutics currently holds about 145.71 M in cash with (56.19 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.93, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check Werewolf Therapeutics Probability Of Bankruptcy
Ownership AllocationWerewolf Therapeutics retains a total of 44.83 Million outstanding shares. Over half of Werewolf Therapeutics' outstanding shares are owned by institutional investors. These institutional investors are typically referred to as corporate investors that purchase positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company shows, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check Werewolf Ownership Details
Werewolf Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Dc Funds, Lp | 2024-12-31 | 589.1 K | |
| State Street Corp | 2024-12-31 | 426.8 K | |
| Northern Trust Corp | 2024-12-31 | 244.4 K | |
| Alyeska Investment Group, L.p. | 2024-12-31 | 235.7 K | |
| Dimensional Fund Advisors, Inc. | 2024-12-31 | 194.7 K | |
| Goldman Sachs Group Inc | 2024-12-31 | 141.8 K | |
| Two Sigma Advisers, Llc | 2024-12-31 | 139.1 K | |
| Morgan Stanley - Brokerage Accounts | 2024-12-31 | 138.1 K | |
| Bridgeway Capital Management, Llc | 2024-12-31 | 109.6 K | |
| Ra Capital Management, Llc | 2024-12-31 | 6.1 M | |
| Mpm Asset Management, Llc | 2024-12-31 | 4.3 M |
Werewolf Therapeutics Historical Income Statement
Werewolf Stock Against Markets
Werewolf Therapeutics Corporate Management
| Randi MD | Chief Officer | Profile | |
| Timothy CPA | Treasurer CFO | Profile | |
| Cynthia SeidelDugan | Chief Officer | Profile | |
| Ellen MBA | Chief Officer | Profile | |
| Daniel Hicklin | CEO, Founder | Profile | |
| William Winston | Senior Research | Profile | |
| Chulani Karunatilake | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Werewolf Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in housing. For more information on how to buy Werewolf Stock please use our How to buy in Werewolf Stock guide.You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Werewolf Therapeutics. If investors know Werewolf will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Werewolf Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.63) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Werewolf Therapeutics is measured differently than its book value, which is the value of Werewolf that is recorded on the company's balance sheet. Investors also form their own opinion of Werewolf Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Werewolf Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Werewolf Therapeutics' market value can be influenced by many factors that don't directly affect Werewolf Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Werewolf Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Werewolf Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Werewolf Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.